Leerink Partnrs Expects Increased Earnings for AstraZeneca

AstraZeneca PLC (NASDAQ:AZN) – Leerink Partnrs upped their Q4 2025 earnings per share estimates for shares of AstraZeneca in a report issued on Sunday, November 9th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn $1.18 per share for the quarter, up from their prior forecast of $1.11. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share.

A number of other equities analysts have also commented on AZN. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Jefferies Financial Group initiated coverage on AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Trading Down 1.6%

Shares of AZN opened at $87.68 on Wednesday. AstraZeneca has a 1-year low of $61.24 and a 1-year high of $89.32. The company has a market capitalization of $271.93 billion, a P/E ratio of 32.96, a P/E/G ratio of 1.52 and a beta of 0.34. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The firm’s 50 day simple moving average is $81.85 and its 200 day simple moving average is $75.95.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The firm had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the company posted $2.08 EPS.

Institutional Trading of AstraZeneca

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. NewSquare Capital LLC boosted its position in AstraZeneca by 149.3% during the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after buying an additional 218 shares during the period. Larson Financial Group LLC grew its stake in shares of AstraZeneca by 297.9% in the first quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after purchasing an additional 289 shares during the last quarter. Richardson Financial Services Inc. raised its position in AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after purchasing an additional 149 shares during the last quarter. Costello Asset Management INC purchased a new stake in AstraZeneca in the 1st quarter worth approximately $29,000. Finally, Rakuten Investment Management Inc. bought a new stake in shares of AstraZeneca in the 3rd quarter worth approximately $31,000. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.